This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kim, S. I. Articles by Park, Y. S. Search for Related Content PubMed PubMed Citation Articles by Kim, S. I. Articles by Park, Y. S.

Inhibitory Effect of the Salmosin Gene Transferred by Cationic Liposomes on the Progression of B16BL6 Tumors¹

Department of Biomedical Laboratory Science and Institute of Health Science, Yonsei University, Wonju 220-710, South Korea [S. I. K., K. S. K., H. S. K., Y. S. P.]; Department of Biochemistry, College of Science, Yonsei University, Seoul 120-749, Republic of Korea [D. S. K.]; and Cardiovascular Research Institute and BK 21 Project for Medical Sciences, Yonsei University College of Medicine, Seoul 120-752, Republic of Korea [K. H. C., Y. J.]

Salmosin is a novel disintegrin containing the Arg-Gly-Asp sequence that significantly inhibits platelet aggregation, basic fibroblast growth factor-induced endothelial cell proliferation, and tumor progression by antagonizing integrin-mediated cell interactions. Previously, it was shown that daily administration of salmosin was able to inhibit tumor-derived angiogenesis and adherence and proliferation of tumor cells, resulting in suppression of tumor progression. However, it is very difficult to maintain a therapeutic level of salmosin in the blood by systemic administration of the protein. Hence, an alternative strategy for antiangiogenic cancer therapy, based on the in vivo expression of the salmosin gene administered with cationic liposomes, was investigated. The salmosin peptides expressed in vitro inhibited the proliferation of bovine capillary endothelial cells in a dose-dependent manner, presumably as a result of inhibition of cell adhesion mediated via _vß₃ integrin. Subcutaneous administration of the salmosin gene resulted in systemic expression of the gene product and concomitant inhibition of the growth of B16BL6 melanoma cells. Suppression of pulmonary metastases, verified by experimental and spontaneous metastasis models in mice, also resulted from salmosin gene treatment. These results suggest that administration of the salmosin gene complexed to cationic liposomes is effective in maintaining antiangiogenic salmosin at an effective therapeutic level and may be clinically applicable to anticancer gene therapy.

This article has been cited by other articles:

				F. Frausin, V. Scarcia, M. Cocchietto, A. Furlani, B. Serli, E. Alessio, and G. Sava Free Exchange across Cells, and Echistatin-Sensitive Membrane Target for the Metastasis Inhibitor NAMI-A (Imidazolium trans-Imidazole Dimethyl Sulfoxide Tetrachlororuthenate) on KB Tumor Cells J. Pharmacol. Exp. Ther., April 1, 2005; 313(1): 227 - 233. [Abstract] [Full Text] [PDF]

				S. Swenson, F. Costa, R. Minea, R. P. Sherwin, W. Ernst, G. Fujii, D. Yang, and F. S. Markland Jr. Intravenous liposomal delivery of the snake venom disintegrin contortrostatin limits breast cancer progression Mol. Cancer Ther., April 1, 2004; 3(4): 499 - 511. [Abstract] [Full Text] [PDF]